Showing results (11-20 of 497) with videos related to
Sort By:
Pageof 50
Archives of Pathology & Laboratory Medicine|November 26, 2019
Contemporary Renal Tumor Categorization With Biomarker and Translational Updates: A Practical ReviewAlexander S Taylor, Daniel E Spratt, Saravana M Dhanasekaran, et al.Translational Andrology and Urology|July 28, 2018
Genomic biomarkers in prostate cancerZachary Kornberg, Matthew R Cooperberg, Daniel E Spratt, et al.American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|September 21, 2018
Management of Biochemically Recurrent Prostate Cancer: Ensuring the Right Treatment of the Right Patient at the Right TimeDaniel E Spratt, Deaglan J McHugh, Michael J Morris, et al.Nature Reviews. Clinical Oncology|June 2, 2016
Translational and clinical implications of the genetic landscape of prostate cancerDaniel E Spratt, Zachary S Zumsteg, Felix Y Feng, et al.The Lancet. Oncology|June 15, 2016
Vessel-sparing radiation and functional anatomy-based preservation for erectile function after prostate radiotherapyJae Y Lee, Daniel E Spratt, Adam L Liss, et al.NPJ Breast Cancer|October 16, 2020
ARe we there yet? Understanding androgen receptor signaling in breast cancerAnna R Michmerhuizen, Daniel E Spratt, Lori J Pierce, et al.American Journal of Clinical Oncology|October 10, 2023
Insurance Denial of Care for Randomized Controlled Trial-Eligible Patients: Incidence and Success Rate of Peer-To-Peer Authorization in Allowing Patients to Remain Trial-EligibleShearwood McClelland, Melissa Brately, Raed J Zuhour, et al.Future Oncology (London, England)|March 7, 2025
The impact of concomitant therapies on the efficacy and safety of relugolix in advanced prostate cancerNeal D Shore, Daniel J George, Daniel E Spratt, et al.Biometrical Journal. Biometrische Zeitschrift|May 17, 2017
Comparison of joint modeling and landmarking for dynamic prediction under an illness-death modelKrithika Suresh, Jeremy M G Taylor, Daniel E Spratt, et al.Journal of the National Cancer Institute|April 15, 2024
A population-based study of COVID-19 mortality risk in US cancer patientsKyle A Mani, Xue Wu, Daniel E Spratt, et al.Pageof 50